HOME >> BIOLOGY >> NEWS
Genomes of tiny microbes yield clues to global climate change

WALNUT CREEK, CA By analyzing the genomes of several microscopic ocean-dwelling organisms sequenced at the U.S. Department of Energy's Joint Genome Institute (JGI), scientists are gaining new insights into how the planet's oceans affect its climate.

Comparative studies of four types of cyanobacteria "photosynthetic" microbes that derive energy from sunlight, just like plants were published today on the websites of the journals Nature and Proceedings of the National Academy of Sciences (PNAS). Three of the microbes two strains of Prochlorococcus and one of Synechococcus were among the first organisms to have their DNA sequenced at JGI in the late 1990s, and are the first ocean bacteria to be sequenced.

Cyanobacteria are important in part because of their ability to turn sunlight and carbon into organic material. As the smallest yet most abundant photosynthetic organisms in the oceans, cyanobacteria play a critical role in regulating atmospheric carbon dioxide, a chief contributor to global climate change. Scientists estimate that Prochlorococcus and Synechococcus remove about 10 billion tons of carbon from the air each year as much as two-thirds of the total carbon fixation that occurs in the oceans.

Patrick Chain, a biologist at Lawrence Livermore National Laboratory (LLNL) and co-author of the two Nature papers, said the three cyanobacteria sequenced by JGI were "hand-picked" to help scientists "begin to understand the physiological and genetic controls of photosynthesis, nitrogen fixation and carbon cycling." The sequencing was funded by the DOE Office of Science's Office of Biological and Environmental Research as part of its mission to study climate change and carbon management.

"While many questions remain," said Dr. Raymond L. Orbach, director of DOE's Office of Science, "it's clear that Prochlorococcus and Synechococcus play an immensely significant role in photosynthetic ocean carbon sequestration. Having the completed
'"/>

Contact: Charles Osolin
osolin1@llnl.gov
925-296-5643
DOE/Joint Genome Institute
13-Aug-2003


Page: 1 2 3

Related biology news :

1. ORNL receives $21.7 million for DOEs Genomes to Life
2. Genomes on chips boon to cancer research
3. Software Helps Decipher Genomes Of Higher Organisms
4. Finding the hole in the defenses of cavity-creating microbes
5. Figs may inhibit growth and survival of harmful microbes in food
6. Discovery of tiny microbes in ancient Greenland glacier may define limits for life on Earth
7. Small, cold, & hungry: Ultra-small microbes from 120,000-year-old glacier ice sample
8. Antibiotics alter GI tract microbes and increase lung sensitivity to allergens
9. Researchers discover 1.2 million new genes in Sargasso Sea microbes
10. Fuel-cell microbes double duty: treat water, make energy
11. Mouth microbes may help shape immune system, says Stanford research team

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Genomes tiny microbes yield clues global climate change

(Date:5/7/2015)... , May 7, 2015 ... sensors, FPC1022 and FPC1035, FPC,s smallest touch fingerprint ... are mainly considered for integration on the backside ... smartphone OEMs increased possibilities to integrate touch fingerprint ... size also improves possibilities for module manufacturers to ...
(Date:4/27/2015)... Profile Solutions, Inc. (OTC: PSIQ), a leading ... pleased to announce that Dr Gerry Bedore ... of its scientific advisory board. ... leader in technology-enhanced learning models. He was a co-founder ... studies and books focused on online student success and ...
(Date:4/14/2015)... , April 14, 2015  HYPR Corp. ... Online (FIDO ® ) Alliance tm , an ... FIDO members commit to share technology and collaborate ... that are interoperable, more secure and private, and ... biometric identity verification that protects sensitive user information ...
Breaking Biology News(10 mins):FPC Introduces its Smallest Touch Fingerprint Sensors to Date 2Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 2Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 4HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3
(Date:5/21/2015)... NOVATO, Calif. , May 21, 2015 /PRNewswire-USNewswire/ ... Orrin Hatch (R-UT) and Amy ... Product Extensions Now Accelerating Cures & Treatments, or ... 150 rare disease patient advocacy organizations, this bipartisan ... effective, and affordable medicines to rare disease patients ...
(Date:5/21/2015)... W. R. Grace & Co. ... Worms, Germany has received good manufacturing practice (GMP) ... International Pharmaceutical Excipient Council (IPEC) Foundation. ... SYLOID® FP brand of pharmaceutical grade excipient silica ... Curtis Bay, Maryland (USA) and Sorocaba, Brazil locations. ...
(Date:5/21/2015)... , May 21, 2015  CytRx Corporation (NASDAQ: ... company specializing in oncology, today announced positive updated ... with aldoxorubicin for the treatment of unresectable glioblastoma ...  The open-label, multisite trial is designed to investigate ... patients whose tumors have progressed following prior treatment ...
(Date:5/21/2015)... Research and Markets ( http://www.researchandmarkets.com/research/84975r/2015_global ... "2015 Global Survey on Flow Cytometry Adoption Trends" ... primary goal of this research is to analyze ... Key information the survey seeks to collect include ... predominantly used applications for flow cytometers, respondents, most ...
Breaking Biology Technology:Advocates Cheer Senate Leaders for Introducing Bipartisan Bill to Increase Number of Rare Disease Treatments 2Grace European Facility Receives GMP Excipient Certification for SYLOID® FP Silica Gel 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7Global Survey on Flow Cytometry Adoption Trends 2015 2
Cached News: